DeepMed Research

JEWISH GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1934-01-01

Employees: -

Market Cap: -

Website: http://www.jgh.ca/

Clinical Trials

Effect of Ketamine on Analgesia Post-Cardiac Surgery

Phase 4

Completed

Conditions: Pain, Postoperative

Interventions: Drug: Ketamine Hydrochloride
Drug: Normal Saline Flush, 0.9% Injectable Solution_#1

First Posted Date: 2016-10-06

Last Posted Date: 2019-09-06

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 80

Registration Number: NCT02925858

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors

Phase 3

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: 68Ga-DOTATATE PET/CT

First Posted Date: 2016-07-21

Last Posted Date: 2025-05-15

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 45

Registration Number: NCT02840149

Locations: 🇨🇦
Jewish General Hospital, Montréal, Quebec, Canada

Apixaban in Hemodialysis

Phase 4

Completed

Conditions: End-stage Renal Disease

Interventions: Drug: apixaban

First Posted Date: 2016-02-03

Last Posted Date: 2016-08-30

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 7

Registration Number: NCT02672709

Locations: 🇨🇦
Jewish General Hospital, Montreal, Canada

Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In Newly Diagnosed Advanced Cancer

Phase 3

Completed

Conditions: Advanced Cancer

Interventions: Drug: Meaning-Making intervention (MMi)
Behavioral: Empathic Visitor

First Posted Date: 2015-10-22

Last Posted Date: 2021-01-08

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 179

Registration Number: NCT02583932

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦
McGill University Health Centre (MUHC), Montreal, Quebec, Canada

Does Bowel Stimulation Before Loop Ileostomy Closure Reduce Postoperative Ileus?

Not Applicable

Completed

Conditions: Postoperative Ileus

Interventions: Procedure: Bowel stimulation
Drug: Nestle Resource

First Posted Date: 2015-09-24

Last Posted Date: 2022-08-18

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 101

Registration Number: NCT02559635

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department

Terminated

Conditions: Splenomegaly
Infectious Mononucleosis

First Posted Date: 2015-06-04

Last Posted Date: 2020-10-06

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 200

Registration Number: NCT02463669

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦
CHU Sainte-Justine, Montreal, Quebec, Canada

Loop Ileostomy With Colonic Lavage for Fulminant Clostridium Difficile Colitis

Not Applicable

Terminated

Conditions: Fulminant Clostridium Difficile Colitis

Interventions: Procedure: Total Abdominal Colectomy with end ileostomy
Procedure: Loop Ileostomy with colonic lavage

First Posted Date: 2015-01-27

Last Posted Date: 2019-12-20

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 12

Registration Number: NCT02347280

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

Feasibility Study of a Home-based Physical Activity Intervention for Family Caregivers of People With Advanced Cancer

Not Applicable

Completed

Conditions: Self Care
Family Caregivers

Interventions: Behavioral: Physical activity intervention
Other: Usual care

First Posted Date: 2014-08-07

Last Posted Date: 2015-03-31

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 28

Registration Number: NCT02211092

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: INGAP Peptide, Ustekinumab

First Posted Date: 2014-07-30

Last Posted Date: 2017-05-30

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 5

Registration Number: NCT02204397

Locations: 🇨🇦
Montreal General Hospital, Montreal, Quebec, Canada

RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment

Phase 2

Completed

Conditions: Invasive Breast Cancer

Interventions: Device: Tumor RDA biopsy

First Posted Date: 2014-07-15

Last Posted Date: 2015-02-04

Lead Sponsor: Jewish General Hospital

Target Recruit Count: 30

Registration Number: NCT02190227

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy